Active Ingredient History
Evofosfamide is an investigational hypoxia-activated prodrug that is in clinical development for cancer treatment. The prodrug is activated only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Biliary Tract Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Esophageal Neoplasms (Phase 1)
Gastrointestinal Stromal Tumors (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hypoxia (Phase 1)
Kidney Neoplasms (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Liver Neoplasms (Phase 1/Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 1)
Neoplasms (Phase 1)
Neuroendocrine Tumors (Phase 2)
Pancreatic Neoplasms (Phase 3)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 1/Phase 2)
Sarcoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue